Search
Bremzalerbart
go.drugbank.com/drugs/DB19417InvestigationalBremzalerbart is under investigation in clinical trial NCT06602739 (A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen
Atisnolerbart
go.drugbank.com/drugs/DB19418InvestigationalAtisnolerbart is under investigation in clinical trial NCT06602739 (A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen
LAX-101
go.drugbank.com/drugs/DB05301InvestigationalThe molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements. … The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical.
Resiniferatoxin
go.drugbank.com/drugs/DB06515InvestigationalResiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission
Trevogrumab
go.drugbank.com/drugs/DB15159Investigationaland Healthy Adult Men). … Trevogrumab is under investigation in clinical trial NCT02943239 (Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women
AT2220
go.drugbank.com/drugs/DB05200InvestigationalAT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.
AMG 108
go.drugbank.com/drugs/DB05545InvestigationalAMG 108 was investigated for use as an antirheumatic agent.
Lucitanib
go.drugbank.com/drugs/DB11845InvestigationalLucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.
Dihydrocapsiate
go.drugbank.com/drugs/DB15398InvestigationalDihydrocapsiate is under investigation in clinical trial NCT00999297 (Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate).
TCB-008
go.drugbank.com/drugs/DB18352InvestigationalTCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.